Dr. Daver on the Next Steps for Menin Inhibitors in AML

Video

In Partnership With:

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Naval Daver, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps for menin inhibitors in acute myeloid leukemia (AML).

Optimization of the management of differentiation syndrome (DS) is needed in AML because DS has been seen more frequently and at higher potency compared with what has previously been seen with other therapies, such as IDH inhibitors, Daver explains. Another important step is to move menininhibitors into combination regimens to be used early in the disease course. This could spare the patient years of single-agent therapy in a space where almost all targeted therapies perform better when combined with other agents, Daver adds.

Ultimately, a critical step is to have several menin inhibitors approved for use in AML, Daver continues. Although menin inhibitors are associated with some toxicities, they also construe more power for differentiation, which makes it possible to optimize and individualize treatment, Daver concludes.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD